Active, Not Recruiting
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
NCT06522386
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- MD Anderson Cancer Center Houston, Texas, United States